Clinical trial NCT02232204: Sleep and Ventricular Arrhythmias Study
Official title: Sleep in Cardiac Patients With Implantable Cardioverter Defibrillators (ICD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cardiac Arrhythmia
Implantable Defibrillator User
Insomnia
Keywords: insomnia
implantable cardioverter defibrillator
cardiac arrhythmia
cognitive behavioral treatment
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2014-09-05
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single-center, randomized controlled trial study design. Enrolled participants have a cardiovascular condition for which they are undergoing implantable cardioverter defibrillator (ICD) therapy and comorbid insomnia. Participants were randomized to a behavioral intervention for insomnia in ICD patients or a waitlist control. The treatment intervention period lasted 4 weeks with a telephone booster session administered at 3 month follow-up. The objective of the study is to examine the impact of a brief therapy combining established behavioral approaches to treating insomnia with novel components to target negative cognitions and anxieties associated with cardiac disease and ICD implantation. Primary patient outcomes include sleep, psychological functioning, daytime functioning, cardiac functioning, cognitive performance, and ICD adjustment.

Detailed description: Participants will be asked to review the informed consent form and consent to the study prior to beginning any study procedure.

There are six phases of this study: (1) an in-person interview, (2) an in-home single night sleep recording, (3) a two-week baseline period, (4) a 4-week treatment period, (5) a follow-up period immediately after the completion of treatment, (6) and a two-week follow-up period 3-months after the treatment period.

During the interview, participants will be asked questions about their sleep, cardiac, and ICD history. Participants will then visit the University of Florida for a medical history and will be connected to machinery to monitor their sleep. Participants will return home to sleep while still connected to the machine and will return the machine to the University of Florida the next day. A third visit will consist of completing questionnaires and a computerized neurocognitive performance battery to assess several areas of cognitive functioning. Participants will then go home and with brief daily diaries to complete for two weeks while also wearing an actigraph (wristwatch-like device) that measures arm movements to detect sleep/wake during that time.

Participants will then be randomized to (a) the brief cognitive behavioral therapy for insomnia (CBTi) in ICD patients group or (b) the waitlist control group. The treatment consists of 2 weeks of in-person therapy and 2 weeks of therapy conducted over the telephone. Participants assigned to waitlist control will be offered therapy at no cost at the end of the study. Throughout the 4 treatment weeks, participants in both groups will be asked to complete daily sleep diaries.

A follow-up period consisting of two weeks, during which participants will wear the actigraph and complete daily sleep diaries, will take place immediately after treatment completion. Participants will travel to the University two times during this follow-up period in order to pick-up and then return the actigraph and sleep diaries, and will once again complete the questionnaires and neurocognitive testing battery at the end of the 2nd visit. A final follow-up period will occur 3-months following treatment, which will involve visits to the University to pick up the daily sleep diaries and actigraph for sleep monitoring, and then returning these items after completion 2-weeks later. Upon returning the diary and actigraph, participants will complete questionnaires and then be debriefed by study personnel.

Eligibility criteria: Inclusion Criteria:

* Current ICD implantation (single or dual lead ICD, ICD and pacemaker)
* Diagnosis of insomnia
* No sleep medications for at least 1 month, or stable on medications for at least 6 months
* Willing to be randomly assigned to treatment
* Able to read and understand English

Exclusion Criteria:

* Sleep disorder other than insomnia
* Significant medical condition other than cardiac disease
* Severe untreated psychopathology
* Neurological disorder
* Cognitive impairment

Primary outcomes:
measure: Change in subjective and objective sleep
timeFrame: Change from baseline to the two study follow-ups (immediately and 3-months following treatment)
Secondary outcomes:
measure: Change in psychological functioning
timeFrame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
measure: Change in daytime functioning
timeFrame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
measure: Change in quality of life
timeFrame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
measure: Change in cardiac functioning
timeFrame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment)
measure: Change in device adjustment
timeFrame: Change from baseline to the two follow-up periods (immediately and 3-months following treatment
measure: Change in cognitive functioning
timeFrame: Change from baseline to immediately after treatment
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida Aging
state: Florida
Study officials:
affiliation: University of Florida
name: Christina S McCrae, PhD
role: PRINCIPAL_INVESTIGATOR
References: